Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
46 hedge funds and large institutions have $39.1M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 21 closing their positions.
12% less funds holding
Funds holding: 52 → 46 (-6)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
90% less capital invested
Capital invested by funds: $396M → $39.1M (-$357M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$5.17M |
| 2 |
Morgan Stanley
New York
|
+$4.86M |
| 3 |
Two Sigma Advisers
New York
|
+$4.36M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.8M |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$46.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$28.3M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$23M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.9M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$9.46M |
STSA Hedge Fund Activity: Q3 2020 in Review
46 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q3 2020, worth a combined $39.1M — down 90% from $396M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of STSA and 15 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 10 added.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $5.17M. The largest seller was Wellington Management Group, exiting entirely with an estimated $46.3M sold.
- 46 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q3 2020, down from 52 in Q2 2020.
- Funds reported $39.1M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 90% quarter-over-quarter.
- 15 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 21 closed out, a net change of -6 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Two Sigma Investments, an estimated $5.17M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Wellington Management Group, an estimated $46.3M sold.
Based on aggregated 13F filings for Q3 2020.